PILL:ARCA-Direxion Daily Pharmaceutical & Medical Bull 2X Shares (USD)

ETF | Trading--Leveraged Equity | NYSE Arca

Last Closing

USD 7.37

Change

0.00 (0.00)%

Market Cap

USD 1.08M

Volume

0.06M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

The investment seeks daily investment results, before fees and expenses, of 200% of the performance of the Dynamic Pharmaceutical Intellidex Index. The fund, under normal circumstances, creates long positions by investing at least 80% of its assets in the securities that comprise the Dynamic Pharmaceutical Intellidex Index and/or financial instruments that provide leveraged and unleveraged exposure to the index. The index consists of common shares of U.S. pharmaceutical companies. These companies are principally engaged in research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. The fund is non-diversified.

Inception Date: 15/11/2017

Primary Benchmark: Dynamic Pharmaceutical Intellidex USD

Primary Index: S&P 500 TR USD

Gross Expense Ratio: 6.74%

Management Expense Ratio: 0.98 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Holdings

N/A

Symbol Company Name Allocation
CRTTF Cortus Metals Inc 3.98 %
Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-28 )

Largest Industry Peers for Trading--Leveraged Equity

Symbol Name Mer Price(Change) Market Cap
SOXL Direxion Daily Semiconductor B.. 1.10 %

N/A

USD 9.92B
FNGU MicroSectors FANG+ Index 3X Le.. 0.00 %

N/A

USD 7.96B
QLD ProShares Ultra QQQ 0.95 %

N/A

USD 7.84B
SSO ProShares Ultra S&P500 0.90 %

N/A

USD 5.60B
UPRO ProShares UltraPro S&P500 0.92 %

N/A

USD 4.27B
TECL Direxion Daily Technology Bull.. 1.17 %

N/A

USD 3.43B
YINN Direxion Daily FTSE China Bull.. 1.02 %

N/A

USD 1.61B
USD ProShares Ultra Semiconductors 0.95 %

N/A

USD 1.16B
UDOW ProShares UltraPro Dow30 0.95 %

N/A

USD 0.91B
LABU Direxion Daily S&P Biotech Bul.. 1.14 %

N/A

USD 0.82B

ETFs Containing PILL

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Leveraged Equity) Market Performance vs. Exchange (NYSE Arca)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.90% 24% F 25% F
Dividend Return 1.01% 50% F 15% F
Total Return -3.90% 23% F 21% F
Trailing 12 Months  
Capital Gain -4.90% 24% F 25% F
Dividend Return 1.01% 50% F 15% F
Total Return -3.90% 23% F 21% F
Trailing 5 Years  
Capital Gain -69.99% 20% F 6% D-
Dividend Return 1.14% 18% F 4% F
Total Return -68.85% 18% F 5% F
Average Annual (5 Year Horizon)  
Capital Gain 57.85% 81% B- 94% A
Dividend Return 58.40% 81% B- 94% A
Total Return 0.55% 38% F 15% F
Risk Return Profile  
Volatility (Standard Deviation) 392.89% 15% F 3% F
Risk Adjusted Return 14.86% 25% F 30% F
Market Capitalization 1.08M N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.